Haemonetics Corporation today announced that William P. Burke will join the Company as Chief Financial Officer, effective August 8, 2016. In this role, he will oversee the Company’s treasury, controllership and accounting, investor relations, tax and financial planning and analysis functions.
Mr. Burke will join the Company directly from Medtronic, Inc. where he has served as Chief Integration Officer for the integration of Covidien into Medtronic since June 2015, filling the key role of principal operating officer for the integration management office. Previously, he held various Finance positions of increasing responsibility over a 20-year career with Covidien and predecessor companies, including CFO – Europe, Vice President of Corporate Strategy and Portfolio Management, and Vice President of Financial Planning and Analysis.
Christopher Simon, Haemonetics’ CEO, stated: “Bill Burke is a valuable addition to our team at an important point in time. He is a thoughtful, pragmatic leader with a strong background in all elements of strategy and finance, deep knowledge of the medical device industry and a proven ability to build strong teams that deliver peak performance amid complex change.”
Source: Haemonetics
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
